EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Sponsors
Efranat Ltd.
Conditions
Recurrent Respiratory PapillomatosisSolid Tumors
Phase 1
Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors
CompletedNCT02052492
Start: 2014-05-31End: 2017-05-31Updated: 2017-06-20
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
NCT02854761
Start: 2016-09-30Target: 6Updated: 2016-08-03